All In Biotech

Drug Trial Radar · NCT05353439

Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination With Topotecan and Pembrolizumab in Recurrent Small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

22

Actual

Start

Jul 27, 2022

Primary completion

Feb 11, 2026

Study completion Apr 21, 2026

Sponsor

Sponsor type
NIH
First posted
Apr 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I trial tests the safety, side effects, and best dose of tazemetostat in combination with topotecan and pembrolizumab in treating patients with small cell lung cancer that has come back after a period of improvement (recurrent). Tazemetostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tazemetostat in combination with topotecan and pembrolizumab may shrink or stabilize recurrent small cell lung cancer.

Conditions

  • Extensive Stage Lung Small Cell Carcinoma
  • Limited Stage Lung Small Cell Carcinoma
  • Platinum-Resistant Lung Small Cell Carcinoma
  • Platinum-Sensitive Lung Small Cell Carcinoma
  • Recurrent Extensive Stage Lung Small Cell Carcinoma
  • Recurrent Lung Small Cell Carcinoma

Interventions

  • Biopsy ProcedureProcedure

    Undergo biopsy

  • Biospecimen CollectionProcedure

    Undergo collection of blood

  • Computed TomographyProcedure

    Undergo CT scan

  • PembrolizumabBiological

    Given IV

  • Tazemetostat HydrobromideDrug

    Given PO

  • Topotecan HydrochlorideDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (Dose-escalation Cohort) of Tazemetostat in Combination With Topotecan and PembrolizumabTime frame: Up to 21 days (cycle 1)
  2. Incidence of Adverse Events (Expansion Cohort) by Type and Grade in the Expansion CohortTime frame: Up to 3 years
  3. Incidence of Grade 3 or Above Adverse Events by Type Related or Possibly Related to Study Treatment in the Dose Escalation CohortTime frame: Start of treatment through 30 days post last dose, an average of 112.33 days or 3.22 months

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Keck Medicine of USC Koreatown

    Los Angeles, California

  • Los Angeles General Medical Center

    Los Angeles, California

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California

  • USC Norris Oncology/Hematology-Newport Beach

    Newport Beach, California

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia

  • Northwestern University

    Chicago, Illinois

  • University of Kentucky/Markey Cancer Center

    Lexington, Kentucky

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland

  • NCI - Center for Cancer Research

    Bethesda, Maryland

  • Montefiore Medical Center-Einstein Campus

    The Bronx, New York

  • Montefiore Medical Center - Moses Campus

    The Bronx, New York

  • Wake Forest University at Clemmons

    Clemmons, North Carolina

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina

  • UT Southwestern/Simmons Cancer Center-Dallas

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.